Silence Therapeutics plc (SLN) /
The cash flow of Silence Therapeutics plc over the past 4 years
Chart Silence Therapeutics plc: operating cash flow, capital expenditures, free cash flow, fiscal 2022–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Silence Therapeutics plc's operating cash flow was -$62.27M and its capital expenditures $55K, leaving free cash flow of -$62.33M. Free cash flow was below zero in all 4 years shown. It ranged from -$67.85M in fiscal 2024 to -$49.52M in fiscal 2023. Capital expenditures were highest in fiscal 2024, at $211K.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$62.27M | $55K | -$62.33M |
| 2024ended Dec 31, 2024 | -$67.64M | $211K | -$67.85M |
| 2023ended Dec 31, 2023 | -$49.46M | $56K | -$49.52M |
| 2022ended Dec 31, 2022 | -$57.04M | $173K | -$57.22M |
Fiscal years as Silence Therapeutics plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Silence Therapeutics plc
- The revenue of Silence Therapeutics plc
- The profitability of Silence Therapeutics plc
- The debt of Silence Therapeutics plc
- All of Silence Therapeutics plc's financials, charted
Companies of a similar size
- GRBKGreen Brick Partners, Inc.
- ASANAsana, Inc.
- CWKCushman & Wakefield Ltd.
- FBKFB FINANCIAL CORPORATION
- BTUPEABODY ENERGY CORP
Not investment advice. This page shows what Silence Therapeutics plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.